China’s cutting-edge drug developers are feeling the pinch from a continued contraction in investment, with some having to make massive layoffs or abandon non-core businesses to survive what has been dubbed a “capital winter.”
China’s cutting-edge drug developers are feeling the pinch from a continued contraction in investment, with some having to make massive layoffs or abandon non-core businesses to survive what has been dubbed a “capital winter.”
[财新双语通产品,是为有双语需求读者专门订制的优惠产品, 按此可享超值优惠订阅。]